DE60036102T2 - Purinderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen - Google Patents

Purinderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen Download PDF

Info

Publication number
DE60036102T2
DE60036102T2 DE60036102T DE60036102T DE60036102T2 DE 60036102 T2 DE60036102 T2 DE 60036102T2 DE 60036102 T DE60036102 T DE 60036102T DE 60036102 T DE60036102 T DE 60036102T DE 60036102 T2 DE60036102 T2 DE 60036102T2
Authority
DE
Germany
Prior art keywords
amino
cyclopentyl
trans
formula
aminocyclohexyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60036102T
Other languages
German (de)
English (en)
Other versions
DE60036102D1 (de
Inventor
Jean-Luc Haesslein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Publication of DE60036102D1 publication Critical patent/DE60036102D1/de
Application granted granted Critical
Publication of DE60036102T2 publication Critical patent/DE60036102T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60036102T 1999-05-21 2000-05-18 Purinderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen Expired - Fee Related DE60036102T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9906456A FR2793794B1 (fr) 1999-05-21 1999-05-21 Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
FR9906456 1999-05-21
PCT/FR2000/001335 WO2000071543A1 (fr) 1999-05-21 2000-05-18 Derives de la purine, leur procede de preparation, et compositions pharmaceutiques les contenant

Publications (2)

Publication Number Publication Date
DE60036102D1 DE60036102D1 (de) 2007-10-04
DE60036102T2 true DE60036102T2 (de) 2008-05-15

Family

ID=9545846

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60036102T Expired - Fee Related DE60036102T2 (de) 1999-05-21 2000-05-18 Purinderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen

Country Status (33)

Country Link
US (2) US7122669B1 (OSRAM)
EP (1) EP1183256B1 (OSRAM)
JP (1) JP2003500407A (OSRAM)
KR (1) KR100707895B1 (OSRAM)
CN (1) CN1298719C (OSRAM)
AP (1) AP1477A (OSRAM)
AR (1) AR035317A1 (OSRAM)
AT (1) ATE370951T1 (OSRAM)
AU (1) AU4764500A (OSRAM)
BR (1) BR0011282A (OSRAM)
CA (1) CA2374714A1 (OSRAM)
CZ (1) CZ20014163A3 (OSRAM)
DE (1) DE60036102T2 (OSRAM)
DK (1) DK1183256T3 (OSRAM)
DZ (1) DZ3166A1 (OSRAM)
EA (1) EA005072B1 (OSRAM)
ES (1) ES2290033T3 (OSRAM)
FR (1) FR2793794B1 (OSRAM)
HU (1) HUP0201649A3 (OSRAM)
IL (1) IL146441A0 (OSRAM)
MA (1) MA26791A1 (OSRAM)
MX (1) MXPA01011834A (OSRAM)
NO (1) NO20015659L (OSRAM)
NZ (1) NZ515556A (OSRAM)
PL (1) PL352293A1 (OSRAM)
PT (1) PT1183256E (OSRAM)
SK (1) SK16722001A3 (OSRAM)
TR (1) TR200103349T2 (OSRAM)
TW (1) TWI284130B (OSRAM)
UA (1) UA68441C2 (OSRAM)
WO (1) WO2000071543A1 (OSRAM)
YU (1) YU86601A (OSRAM)
ZA (1) ZA200109602B (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413974B1 (en) * 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
US6479487B1 (en) * 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
US6969720B2 (en) 1999-03-17 2005-11-29 Amr Technology, Inc. Biaryl substituted purine derivatives as potent antiproliferative agents
US6861524B2 (en) * 2000-10-31 2005-03-01 Aventis Pharmaceuticals Inc. Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
ATE426603T1 (de) * 2000-10-31 2009-04-15 Aventis Pharma Inc Acyl- und sulfonylderivative 6,9- disubstitutierter 2-(trans-1,4-diaminocyclohexyl)-purine und ihre verwendung als antiproliferative mittel
FR2818642B1 (fr) * 2000-12-26 2005-07-15 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion
US6667311B2 (en) * 2001-09-11 2003-12-23 Albany Molecular Research, Inc. Nitrogen substituted biaryl purine derivatives as potent antiproliferative agents
US6812232B2 (en) 2001-09-11 2004-11-02 Amr Technology, Inc. Heterocycle substituted purine derivatives as potent antiproliferative agents
CA2463563A1 (en) * 2001-10-12 2003-04-17 Irm Llc Kinase inhibitor scaffolds and methods for their preparation
EP1556129A4 (en) * 2002-10-15 2011-02-09 Irm Llc COMPOSITIONS AND METHODS OF INDUCING OSTEOGENESIS
FR2851248B1 (fr) * 2003-02-18 2005-04-08 Aventis Pharma Sa Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
ES2398239T3 (es) 2003-11-10 2013-03-14 The Scripps Research Institute Composiciones y procedimientos para inducir la desdiferenciación celular
AU2005231440B9 (en) * 2004-04-02 2012-02-23 Dogwood Pharmaceuticals, Inc. Selective antagonists of A2A adenosine receptors
CZ302122B6 (cs) * 2009-01-28 2010-10-20 Univerzita Palackého v Olomouci Substituované deriváty 6-(2-aminobenzylamino)purinu, jejich použití jako léciva a prípravky tyto slouceniny obsahující
WO2012142029A2 (en) 2011-04-10 2012-10-18 Florida A&M University Serms for the treatment of estrogen receptor-mediated disorders
EP3134405B1 (en) 2014-04-25 2019-08-28 Pfizer Inc Heteroaromatic compounds and their use as dopamine d1 ligands
CN114149432B (zh) * 2016-09-30 2024-07-05 斯坦福国际研究院 用于癌症治疗的双重clk/cdk1抑制剂
CZ308029B6 (cs) 2017-03-20 2019-11-06 Univerzita PalackĂ©ho v Olomouci 2,6-Disubstituované-9-cyklopentyl-9H-puriny, jejich použití jako léčiva a farmaceutické přípravky
WO2024127350A1 (en) 2022-12-16 2024-06-20 Astrazeneca Ab 2,6,9-trisubstituted purines

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4008858A1 (de) * 1990-03-20 1991-09-26 Hoechst Ag Substituierte purine, verfahren zu ihrer hertellung sowie ihre verwendung als antivirale mittel
EP0841810B1 (en) * 1991-12-05 2000-06-21 Texas Instruments Incorporated Method to improve a video signal
CA2084222C (en) * 1991-12-06 2004-04-06 David R. Borcherding Novel trans cyclopentanyl purine analogs useful as immunosuppressants
DE69627195T2 (de) * 1995-11-01 2004-01-29 Novartis Ag Purinderivate und verfahren zu ihrer herstellung
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
US6790958B2 (en) * 1996-08-02 2004-09-14 Robert T. Lum Purine inhibitors of cyclin dependent kinase 2 & IKBA
WO1998016528A1 (en) * 1996-10-11 1998-04-23 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
AU735127B2 (en) * 1997-08-07 2001-06-28 Regents Of The University Of California, The Purine inhibitor of protein kinases, G proteins and polymerases
US6413974B1 (en) * 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
US6479487B1 (en) * 1998-02-26 2002-11-12 Aventis Pharmaceuticals Inc. 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
GB9903762D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
FR2818642B1 (fr) * 2000-12-26 2005-07-15 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion

Also Published As

Publication number Publication date
JP2003500407A (ja) 2003-01-07
ES2290033T3 (es) 2008-02-16
WO2000071543A1 (fr) 2000-11-30
DE60036102D1 (de) 2007-10-04
DK1183256T3 (da) 2007-12-03
ZA200109602B (en) 2003-01-29
MXPA01011834A (es) 2002-04-17
NO20015659L (no) 2002-01-18
NO20015659D0 (no) 2001-11-20
US20050187228A1 (en) 2005-08-25
AU4764500A (en) 2000-12-12
US7122669B1 (en) 2006-10-17
DZ3166A1 (fr) 2000-11-30
CN1298719C (zh) 2007-02-07
EP1183256A1 (fr) 2002-03-06
MA26791A1 (fr) 2004-12-20
FR2793794B1 (fr) 2001-07-27
EP1183256B1 (fr) 2007-08-22
CZ20014163A3 (cs) 2002-10-16
EA005072B1 (ru) 2004-10-28
HUP0201649A2 (en) 2002-08-28
NZ515556A (en) 2003-08-29
ATE370951T1 (de) 2007-09-15
IL146441A0 (en) 2002-07-25
PL352293A1 (en) 2003-08-11
US7208598B2 (en) 2007-04-24
AR035317A1 (es) 2004-05-12
UA68441C2 (en) 2004-08-16
BR0011282A (pt) 2002-02-26
TWI284130B (en) 2007-07-21
AP2001002355A0 (en) 2001-12-31
CA2374714A1 (fr) 2000-11-30
CN1361780A (zh) 2002-07-31
HUP0201649A3 (en) 2003-01-28
FR2793794A1 (fr) 2000-11-24
PT1183256E (pt) 2007-11-13
TR200103349T2 (tr) 2002-05-21
KR100707895B1 (ko) 2007-04-17
AP1477A (en) 2005-10-19
EA200101224A1 (ru) 2002-10-31
SK16722001A3 (sk) 2003-01-09
KR20010113975A (ko) 2001-12-28
YU86601A (sh) 2005-07-19

Similar Documents

Publication Publication Date Title
DE60036102T2 (de) Purinderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen
JP7416365B2 (ja) アポトーシス誘発剤
DE69915675T4 (de) Triazolo[4,5-d]pyrimidin-derivate
ES2461967T3 (es) Compuestos de pirrolo[2,3-d]pirimidina
DE69710490T2 (de) Triazolo(4,5-d)pyrimidinyl-derivate und ihre verwendung als medikamente
DE69804964T2 (de) Neue verbindungen
DE69724811T2 (de) Pentafluorobenzensulfonamide und analoge
JP7558977B2 (ja) メチル基及びトリフルオロメチル基を含む二置換スルファミド系選択的bcl-2阻害剤
CA3011549A1 (en) Benzopyrazole compounds and analogues thereof
TW201311651A (zh) 經取代之二胺基甲醯胺及二胺基甲腈嘧啶、其組合物、及以該等治療之方法
DE60016039T2 (de) Verfahren und verbindungen für die hemmung von mrp1
DE60316821T2 (de) Aminobenzothiazolverbindungen mit nos-hemmender wirkung
JP2023062064A (ja) 軟骨形成を誘導するための化合物及び組成物
DE60201819T2 (de) Phenyl-heterocyclyl-ether-derivate als serotonin re-uptake inhibitoren
JP6850887B2 (ja) 置換ピラゾロアゼピン−8−オンおよびそれらのホスホジエステラーゼ阻害剤としての使用
DE60122295T2 (de) Flavon derivate, verfahren zu deren herstellung und deren verwendung als heilmittel
JP2020500920A (ja) 置換ピラゾロアゼピン−4−オンおよびそれらのホスホジエステラーゼ阻害剤としての使用
TW202233620A (zh) Cftr調節劑化合物、組合物及其用途
DE60222459T2 (de) 2-(3-sulfonylamino-2-oxopyrrolidin-1-yl)propanamide als factor xa inhibitoren
EP4448491A2 (en) N-((adamantan-1-yl)carbamoyl)-benzenesulfonamide derivatives as soluble epoxide hydrolase inhibitors for the treatment of hypertension
DE69913499T2 (de) Nucleoside
DE60021859T2 (de) 1, 2, 3, 4-tetrahydro-1-naphthalenamin verbindungen zur therapeutsichen verwendung
AU2006202270A1 (en) Purine derivatives, preparation method and pharmaceutical compositions containing same
AT406675B (de) (-)-(3r)-3-methyl-4-(4-(4-(4-pyridyl) piperazin-1-yl)phenoxy)buttersäure als zellulärer adhäsionsinhibitor
JP2017095358A (ja) プテリン誘導体又はその塩

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee